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ABSTRACT 
Objective: To establish a validated liquid chromatographic method for the quantification of Tenfovir disoproxil fumarate (TENO), Lamivudine 
(LAM) and Nevirapine (NEV) in ternary combination and in its tablet dosage form. 
Methods: The three drugs were well resolved using ODS C18 
Results: The response was a linear function of analyte concentration over the concentration range of 45-105 µg/ml for tenofovir disoproxil 
fumarate, lamivudine and between 30-70 µg/ml for nevirapine with a correlation coefficient>0.9997. The % RSD values of precision and accuracy 
studies were found to be less than 2. 
column (250 x 4.6 mm, 5μm) with a mobile phase consisting of phosphate buffer, pH 3.0-
acetonitrile (60:40, v/v) with a flow rate of 1.0 ml/min at UV detection wavelength 252 nm. The developed method was validated as per ICH guidelines. 
Conclusion: The proposed method was validated as per standard guidelines. The results obtained from assay values were in good agreement with 
the labeled amount of the marketed tablet dosage form RICOVIR-LN. The method holds promise for routine quality control of this ternary 
combination in bulk and pharmaceutical formulations. 
Keywords: Column liquid chromatography, Tenofovir Disoproxil Fumarate, Lamivudine, Nevirapine. 
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INTRODUCTION 
Tenofovir chemically designated as {[(2R)-1-(6-amino-9H-purin-9-yl) 
propan-2-yl) oxy] methyl} phosphonic acid, is an anti-retroviral agent 
currently used in the treatment of HIV. Its mechanism of action involves 
the inhibition of HIV reverse transcriptase activity by competing with 
natural substrate deoxyadenosine5’-triphosphate by DNA chain 
termination. Nevirapine is chemically designated as 2-cyclopropyl-7-
methyl- 2,4,9,15-tetra aza tricyclo [9.4.0.0^{3,8}] pentadeca-
1(15)3,5,7,11,13-hexane-10-one, is an antiretroviral agent used in HIV 
treatment. Its mechanism of action involves binding of reverse 
transcriptase directly and blocks RNA-dependent and DNA–dependent 
polymerase activities by causing disruption of enzyme catalytic site. 
Lamivudine is also an anti-retroviral agent which is chemically 
designated as 4-amino-1-[(2R, 5S)-2-(hydromethyl)-1,3-oxathiolan-5-
yl]-1,2-dihydropyrimidin-2-one, used in the treatment of HIV. Chemical 
structures of these drugs were shown in fig.-1. The combination of three 
drugs used for the treatment of HIV as a ternary combination [1-2]. 
 
 
Fig. 1: Chemical structures of tenofovir disoproxil fumarate (A), 
Nevirapine (B) and Lamivudine (C) 
 
An all-embracing literature search revealed that only one analytical 
method using high-performance liquid chromatography has been 
previously reported for the determination of this combination by 
gradient elution [3]. Few analytical methods based on HPLC, HPTLC, 
UV spectroscopy are available for the determination of these drugs 
individually and in combination with other drugs in different dosage 
forms, but there is no isocratic HPLC method for simultaneous 
quantification of three drugs in combined dosage form [4-14]. 
Keeping this point into consideration, present investigation has been 
undertaken with the objective to develop and validate simple 
isocratic RP-HPLC method for evaluation of this tertiary 
combination of drugs in bulk and tablet dosage form. 
MATERIALS AND METHODS 
Instrument and chromatographic conditions 
The ternary combination of three drugs were well separated by using 
a Shimadzu model LC-20AD HPLC system connected to LC solutions 
software, equipped with an SPD-20A prominence UV detector and 
ODS, C18
Chemicals and reagents 
 column (250x4.6 mm, 5 µm) maintained at 25ºC. Isocratic 
elution was performed using acetonitrile and phosphate buffer, pH 3.0 
(40:60, v/v) with flow rate 1.0 ml/min at UV detection wavelength 
252 nm. 20 µl of sample was injected into the HPLC system. 
Tenofovir disoproxil fumarate, nevirapine and lamivudine standards 
and tablet dosage forms were obtained from Mylan laboratories 
(Hyderabad, India). Milli-Q-water was used throughout the 
experiment. Acetonitrile and methanol (HPLC grade), sodium 
hydroxide, potassium dihydrogen phosphate, orthophosphoric acid 
were purchased from Merck (Mumbai, India). 
Preparation of standard stock solution 
The standard stock solution was prepared by dissolving 75 mg of 
tenofovir diisopropyl fumarate, 50 mg of nevirapine and 75 mg of 
lamivudine in 100 ml of mobile phase to get concentrations of 750 
µg/ml, 500 µg/ml and 750 µg/ml respectively. This stock solution 
was further diluted with mobile phase to get the required 
concentration of drugs. Solutions were filtered through 0.22 µm 
membrane filter prior to injection into HPLC system. 
Assay of commercial tablets 
Twenty tablets of RICOVIR-LN were purchased, weighed and 
crushed into fine powder. An accurately weighed portion of tablet 
powder equivalent to 75 mg, 50 mg and 75 mg of tenofovir 
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disoproxil fumarate, nevirapine and lamivudine respectively was 
transferred into a 100 ml volumetric flask and made up to volume 
with mobile phase. The mixture was sonicated for 30 min and 
filtered to produce a final solution containing 75 µg/ml of tenofovir 
disoproxil fumarate, 50 µg/ml of nevirapine and 75 µg/ml of 
lamivudine respectively. The sample solution (20 µl) was injected 
into the HPLC system under optimized chromatographic conditions 
and peak area was measured from respective chromatograph to 
calculate the concentration of assay sample. 
Method validation 
Validation was done with respect to various parameters, as 
mentioned under ICH guidelines (ICH, Q2 (R1), 2005) [15-18]. 
Linearity 
The linearity of the method was confirmed using a standard solution of 
the combination at different concentrations of analytes within the range 
of 45-105 µg/ml for tenofovir and lamivudine and between 30-70 µg/ml 
for nevirapine. Each solution was analyzed six times, and calibration plot 
was drawn by plotting the peak area against concentration.  
Precision 
Intra-day and inter-day precision were evaluated by determining the 
corresponding responses of standard solutions in six times on the 
same day and on different days (intermediate precision). The results 
were reported in terms of % RSD.  
Accuracy 
For the determination of % recovery, analysed samples were spiked 
with 80%, 100% & 120% level of standard drug and each solution 
was injected into HPLC system in six times and recovery was 
calculated by measuring peak areas. 
Robustness 
Robustness was studied to evaluate the effect of small but deliberate 
variations in the chromatographic conditions at different levels include 
wavelength (±2 nm), the percentage of acetonitrile (±10 %) and flow 
rate (±2 ml/min). One factor at a time was changed to estimate the effect.  
LOD and LOQ 
The limits of detection(LOD) and quantification (LOQ) were 
calculated by the method based on standard deviation(δ) of the 
response in triplicate and the slope (S) of the calibration plot, by use 
of formulae LOD=3.3δ/S and LOQ=10δ/S. 
RESULTS AND DISCUSSION  
The chromatographic conditions were optimized with a view to 
develop a reverse phase LC assay method. No internal standard was 
used, and no extraction or separation step was not involved. The 
optimization of the method parameters was done by fixing one 
variable and changing the other variables among mobile phase 
composition, flow rate and pH of the mobile phase. Tenofovir 
disoproxil fumarate, lamivudine, and nevirapine are partially soluble 
in water and freely soluble in organic solvents, such as methanol and 
acetonitrile. Among the different combinations for the solvent 
system, acetonitrile and phosphate buffer, pH 3.0, was preferred as 
the mixture, resulted in greater response to this drug combination 
after several preliminary investigatory runs. The pH of mobile phase 
was found to be critical because the peak obtained above pH 3.0 of 
buffer was irregular and asymmetric. Changes in the concentration 
of organic modifier often lead to significant changes in separation 
selectivity. Increasing in the buffer content in mobile phase resulted 
in a decrease in the retention time of the drugs. Therefore, a high 
buffer concentration was used at a flow rate of 1.0 ml/min. The peak 
shape and symmetry were found to be good when mobile phase 
composition of 60:40 (v/v) of phosphate buffer and acetonitrile was 
used at a flow rate of 1.0 ml/min at ambient temperature. Under 
these conditions, the analyte peak was well defined with very good 
symmetry, free from tailing and retention time of lamivudine, 
nevirapine, and tenofovir disoproxil fumarate was found to be at 
2.350, 4.533 and 6.157 min respectively. The optimized 
chromatogram of proposed method was shown in fig. 2 and system 
suitability parameters reported in table 1. The method presents 
advantages over previously published methods by the usage of 
readily available mobile phase phosphate buffer and acetonitrile 
with UV-detector and short retention time enabled the analysis of a 
large number of samples with a small quantity of mobile phase, 
leading to its cost effectiveness. The results obtained from assay 
values were in good agreement with the labeled amount of the 
marketed tablet dosage form RICOVIR-LN (table 2). 
Method validation 
The correlation coefficient (R2
The robustness of the method was investigated under a variety of 
conditions with respect to changes in flow rate, wavelength, and 
composition of the mobile phase. The results revealed that the method is 
robust for normally expected variations in chromatographic conditions 
(table 6). The LOD for lamivudine, nevirapine, and tenofovir disoproxil 
fumarate were 1.95, 1.26 and 2.91 µg/ml respectively. The LOQ values of 
lamivudine, nevirapine, and tenofovir disoproxil fumarate were found to 
be 5.92, 3.81 and 8.83 µg/ml. The results strongly advocate that 
developed method is sensitive. 
>0.9997) of the calibration plots 
indicated good linearity in the range of 45-105 µg/ml for 
lamivudine and tenofovir disoproxil fumarate and 30-70 µg/ml for 
nevirapine, and optimized conditions of proposed method showed 
in table 3. No significant difference between intra-day and inter-
day precision values revealed that the method was reproducible 
(table-4). The % recovery of the method ranged from 98-102 after 
spiking previously analysed samples with 80%, 100% and 120% 
of additional drug and % RSD values less than 2 indicates the 




Fig. 2: Optimized chromatogram of the proposed method 
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Table 1: System suitability parameters for the proposed method 
Parameter LAM NEV TEN 
Retention time (min) 2.350 4.533 6.157 
Theoretical plates 31173 65349 98331 
Tailing factor 1.640 0.412 1.023 
 
Table 2: Assay for the proposed method 
S formulation Label claim (mg) Amount found (mg) % assay* 
RICOVIR-LN LAM 300 299.65  99.88±0.024 
NEV 200 199.13 99.57±0.124 
TEN 300 297.19 99.07±0.254 
*Mean of three replicates 
 
Table 3: Analytical parameters for the determination of the ternary drug combinations using proposed RP-HPLC method 
Parameters Analyte 
 LAM NEV TEN 
Wavelength (nm) 252 252 252 
Concentration 
Range (µg/ml) 
45-105 30-70 45-105 
Intercept* -65.67 +16.75 -47.35 
Slope* 37.86 51.04 25.30 
Standard deviation* 23.7 19.235 23.717 
% RSD* 0.975 0.7936 1.5086 
Correlation coefficient 0.9998 0.999 0.997 
LOD (µg/ml) 1.95 1.26 2.91 
LOQ (µg/ml) 5.92 3.81 8.83 
*Mean of six determinations 
 
Table 4: Precision data 
Parameters Analyte (% RSD *) 
 LAM NEV TENO 
Intra-day precision 0.29 0.39 1.12 
Inter-day precision 0.243 0.391 1.001 
*Mean of three determinations 
 
Table 5: Recovery data 















20 45.65 101.44 0.291 
100 25 50.57 101.10 0.526 





24 54.81 101.52 0.253 
100 30 61.02 101.70 0.633 





20 44.19 98.22 0.712 
100 25 50.82 101.64 0.625 
120 30 56.35 100.60 0.512 
*Mean of three replicates. 
 
Table 6: Robustness for the proposed method 
Parameter Deliberate change Retention time* Area* 
TEN NEV LAM TEN NEV LAM 
Flow rate 0.8 8.357 6.0166 3.706 1966.98 3043.70 3097.66 
1.2 5.5866 4.045 2.497 1311.07 2035.07 2037.60 
Wavelength 250 8.357 6.016 3.706 1966.9 3043.7 3097.6 
254 5.586 4.045 2.497 1311.0 2035.0 2037.6 
Mobile phase -10 % 5.586 4.045 2.497 1311.07 2037.07 2037.6 
+10 % 8.357 6.016 3.706 1966.98 3043.70 3097.66 
*Average of three replicates 
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CONCLUSION 
Literature survey revealed that isocratic RP-HPLC method was not 
available for simultaneous quantification of lamivudine, nevirapine 
and tenofovir diisopropyl fumarate in ternary mixture and tablet 
dosage form. In present proposed method, the complete separation 
of three analytes was accomplished in less than 7 min with same 
mobile phase composition throughout the analysis, revealed that the 
proposed method is economic and simple than previous gradient 
method. The proposed method was validated as per standard 
guidelines and results obtained from validation proved that the 
method was specific, precise, accurate and robust. The developed 
method was also utilized for assay of commercial tablets, and 
obtained values are good agreement with their labeled claim. These 
advantageous encourage that; the developed method can be routine 
quality control of this ternary combination in bulk and 
pharmaceutical formulations. 
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